BMS, GRYT Health push for diversity in oncology with new initiativenews2021-10-22T08:24:53+00:00October 22nd, 2021|Fierce Pharma|
Novartis has negotiated Zolgensma access for half of the European SMA population, exec says. How’d it get there?news2021-10-21T20:07:54+00:00October 21st, 2021|Fierce Pharma|
Alnylam’s Givlaari wins NICE reversal after offering discount for rare genetic liver condition therapynews2021-10-21T15:20:01+00:00October 21st, 2021|Fierce Pharma|
Johnson & Johnson preps for first CAR-T launch with a new patient support program, a dedicated sales team and morenews2021-10-21T15:16:03+00:00October 21st, 2021|Fierce Pharma|
Pfizer, Merck next-gen pneumococcal vaccines score key CDC panel’s backing on way to rival rolloutsnews2021-10-21T13:44:45+00:00October 21st, 2021|Fierce Pharma|
Moderna, Johnson & Johnson COVID boosters nab FDA nods as agency backs ‘mix-and-match’ approachnews2021-10-21T13:34:25+00:00October 21st, 2021|Fierce Pharma|
Novartis inks deal to manufacture Pfizer COVID-19 vaccines in Slovenianews2021-10-21T12:30:19+00:00October 21st, 2021|Fierce Pharma|
More activist pressure for Merck’s $11.5B Acceleron deal as another hedge fund balks—but BMS appears ready to dealnews2021-10-21T10:02:40+00:00October 21st, 2021|Fierce Pharma|
Automation, portable manufacturing and finding the right partner: Industry vets discuss the coming gene therapy wavenews2021-10-21T04:38:18+00:00October 21st, 2021|Fierce Pharma|
Novavax struggling to meet quality standards in COVID-19 vaccine production push: reportnews2021-10-20T18:19:39+00:00October 20th, 2021|Fierce Pharma|
